Trial Profile
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 May 2022
Price :
$35
*
At a glance
- Drugs AL-002 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Acronyms INVOKE
- Sponsors Alector
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 30 Jul 2021 Results of single ascending dose (SAD) portion of the study of INVOKE trial, presented at the Alzheimer's Association International Conference 2021.
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.